- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00308581
Certolizumab in Crohn's Disease Patients With Loss of Response or Intolerance to Infliximab
Phase IIIb Open-label Induction and Double-blind Comparison of 2 Maintenance Schedules Evaluating Clinical Benefit and Tolerability of Certolizumab Pegol in Crohn's Disease Patients With Prior Loss of Response or Intolerance to Infliximab
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 3
Erweiterter Zugriff
Kontakte und Standorte
Studienorte
-
-
-
Bonheiden, Belgien
-
Brussels, Belgien
-
Genk, Belgien
-
Gent, Belgien
-
Kortrijk, Belgien
-
Leuven, Belgien
-
Liege, Belgien
-
Roeselare, Belgien
-
-
-
-
-
Berlin, Deutschland
-
Hamburg, Deutschland
-
Hannover, Deutschland
-
Herne, Deutschland
-
Kiel, Deutschland
-
Leipzig, Deutschland
-
Minden, Deutschland
-
Munchen, Deutschland
-
Munich, Deutschland
-
-
-
-
-
Aalborg, Dänemark
-
Arhus, Dänemark
-
Copenhagen, Dänemark
-
Herlev, Dänemark
-
-
-
-
-
Amiens, Frankreich
-
Clichy, Frankreich
-
Grenoble, Cedex 9, Frankreich
-
Lille, Frankreich
-
Montpellier, Cédex 5, Frankreich
-
Nice, Frankreich, Cedex 3
-
Paris, Frankreich
-
Pessac, Frankreich
-
Rouen, Frankreich
-
Toulouse, Cedex 9, Frankreich
-
-
-
-
-
Bari, Italien
-
Bologna, Italien
-
Milano, Italien
-
Padova, Italien
-
Palermo, Italien
-
Roma, Italien
-
Torino, Italien
-
-
-
-
-
Calgary, Kanada
-
-
Alberta
-
Edmonton, Alberta, Kanada
-
-
British Columbia
-
Vancouver, British Columbia, Kanada
-
-
Ontario
-
London, Ontario, Kanada
-
Richmond, Ontario, Kanada
-
Toronto, Ontario, Kanada
-
-
-
-
-
Amsterdam, Niederlande
-
Eindhoven, Niederlande
-
Enschede, Niederlande
-
Heerlen, Niederlande
-
Leiden, Niederlande
-
Terneuven, Niederlande
-
Zwolle, Niederlande
-
-
-
-
-
Oslo, Norwegen
-
Tromso, Norwegen
-
-
-
-
-
Goteborg, Schweden
-
Malmo, Schweden
-
Orebro, Schweden
-
Stockholm, Schweden
-
-
-
-
-
Basel, Schweiz
-
Bern, Schweiz
-
Lausanne, Schweiz
-
-
-
-
-
Barcelona, Spanien
-
Madrid, Spanien
-
Oviedo, Spanien
-
Santiago De Compostela, Spanien
-
Sevilla, Spanien
-
Valencia, Spanien
-
-
-
-
California
-
San Francisco, California, Vereinigte Staaten
-
-
Florida
-
Gainesville, Florida, Vereinigte Staaten
-
-
Georgia
-
Atlanta, Georgia, Vereinigte Staaten
-
-
Illinois
-
Chicago, Illinois, Vereinigte Staaten
-
-
Indiana
-
Indianapolis, Indiana, Vereinigte Staaten
-
-
Kentucky
-
Lexington, Kentucky, Vereinigte Staaten
-
Louisville, Kentucky, Vereinigte Staaten
-
-
Louisiana
-
Baton Rouge, Louisiana, Vereinigte Staaten
-
-
Maryland
-
Baltimore, Maryland, Vereinigte Staaten
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten
-
-
Minnesota
-
Rochester, Minnesota, Vereinigte Staaten
-
-
Nebraska
-
Lincoln, Nebraska, Vereinigte Staaten
-
-
New York
-
Great Neck, New York, Vereinigte Staaten
-
New York, New York, Vereinigte Staaten
-
-
North Carolina
-
Chapel Hill, North Carolina, Vereinigte Staaten
-
Charlotte, North Carolina, Vereinigte Staaten
-
-
Ohio
-
Cincinnati, Ohio, Vereinigte Staaten
-
Cleveland, Ohio, Vereinigte Staaten
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Vereinigte Staaten
-
-
Oregon
-
Portland, Oregon, Vereinigte Staaten
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Vereinigte Staaten
-
Pittsburgh, Pennsylvania, Vereinigte Staaten
-
-
South Carolina
-
Charleston, South Carolina, Vereinigte Staaten
-
-
Tennessee
-
Germantown, Tennessee, Vereinigte Staaten
-
Kingsport, Tennessee, Vereinigte Staaten
-
Nashville, Tennessee, Vereinigte Staaten
-
-
Texas
-
Dallas, Texas, Vereinigte Staaten
-
Galveston, Texas, Vereinigte Staaten
-
Houston, Texas, Vereinigte Staaten
-
-
Washington
-
Seattle, Washington, Vereinigte Staaten
-
-
Wisconsin
-
Milwaukee, Wisconsin, Vereinigte Staaten
-
-
-
-
-
Bristol, Vereinigtes Königreich
-
Cambridge, Vereinigtes Königreich
-
Edinburgh, Vereinigtes Königreich
-
London, Vereinigtes Königreich
-
Nottingham, Vereinigtes Königreich
-
Oxford, Vereinigtes Königreich
-
Sheffield, Vereinigtes Königreich
-
-
-
-
-
Innsbruck, Österreich
-
Oberpullendorf, Österreich
-
Wien, Österreich
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Subjects with Crohn's Disease
- Previous treatment failure to Infliximab (intolerance and/or no response)
Exclusion Criteria:
- Obstructive intestinal strictures
- Recent bowel resection
- Proctocolectomy or total colectomy
- Current total parenteral nutrition
- Short bowel syndrome
- All concomitant diseases or pathological conditions that could interfere with Crohn's disease assessment or to be harmful for the well being of the patient
- Previous clinical trials and previous biological therapy that could interfere with the results in the present clinical trial
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Doppelt
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Active 1
Q4W regimen - every 4 weeks: alternatively placebo and 400mg Certolizumab Pegol |
400mg Certolizumab Pegol, Q4W, administered 4-weekly
Andere Namen:
400mg Certolizumab Pegol, Q2W, administered 2-weekly
Andere Namen:
placebo administered 4-weekly in Active 1
|
Experimental: Active 2
Q2W regimen - every 2 weeks: 400 mg Certolizumab Pegol |
400mg Certolizumab Pegol, Q4W, administered 4-weekly
Andere Namen:
400mg Certolizumab Pegol, Q2W, administered 2-weekly
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Response Status With Response Defined as at Least 100 Point Decrease in Crohn's Disease Activity Score (CDAI Score) From Baseline in the Induction Phase
Zeitfenster: Baseline to Week 6
|
Response is defined as at least 100 point decrease in Crohn's Disease Activity Score (CDAI score) from baseline, otherwise there is a non-response. The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity. |
Baseline to Week 6
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Response Status With Response Defined as at Least 100 Point Decrease in CDAI Score From Baseline in the Randomized Maintenance Phase
Zeitfenster: Baseline to Week 26
|
Response is defined as at least 100 point decrease in CDAI score from baseline.
The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease.
A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
A decrease in CDAI over time indicates improvement in disease activity.
|
Baseline to Week 26
|
Response Status With Response Defined as at Least 70 Points Reduction in CDAI Score in the Induction Phase
Zeitfenster: Baseline to Week 6
|
Response is defined as at least 70 points reduction in CDAI score.
The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease.
A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
A decrease in CDAI over time indicates improvement in disease activity.
|
Baseline to Week 6
|
Response Status With Response Defined as at Least 70 Points Reduction in CDAI Score in the Randomized Maintenance Phase
Zeitfenster: Baseline to Week 26
|
Response is defined as at least 70 points reduction in CDAI score.
The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease.
A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
A decrease in CDAI over time indicates improvement in disease activity.
|
Baseline to Week 26
|
Remission Status With Remission Defined as CDAI Score ≤ 150 in the Induction Phase
Zeitfenster: Week 6
|
Remission is defined as CDAI score ≤ 150.
The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease.
A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
A decrease in CDAI over time indicates improvement in disease activity.
|
Week 6
|
Remission Status With Remission Defined as CDAI Score ≤ 150 in the Randomized Maintenance Phase
Zeitfenster: Week 26
|
Remission is defined as CDAI score ≤ 150.
The CDAI score is used to quantify the symptoms with Crohn's Disease.
A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
A decrease in CDAI over time indicates improvement in disease activity.
|
Week 26
|
CDAI Score at Week 2 of the Induction Phase
Zeitfenster: Week 2
|
The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease.
A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
A decrease in CDAI over time indicates improvement in disease activity.
|
Week 2
|
CDAI Score at Week 4 of the Induction Phase
Zeitfenster: Week 4
|
The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease.
A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
A decrease in CDAI over time indicates improvement in disease activity.
|
Week 4
|
CDAI Score at Week 6 of the Induction Phase
Zeitfenster: Week 6
|
The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease.
A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
A decrease in CDAI over time indicates improvement in disease activity.
|
Week 6
|
CDAI Score at Week 8 in the Randomized Maintenance Phase
Zeitfenster: Week 8
|
The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease.
A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
A decrease in CDAI over time indicates improvement in disease activity.
|
Week 8
|
CDAI Score at Week 10 in the Randomized Maintenance Phase
Zeitfenster: Week 10
|
The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease.
A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
A decrease in CDAI over time indicates improvement in disease activity.
|
Week 10
|
CDAI Score at Week 12 in the Randomized Maintenance Phase
Zeitfenster: Week 12
|
The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease.
A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
A decrease in CDAI over time indicates improvement in disease activity.
|
Week 12
|
CDAI Score at Week 14 in the Randomized Maintenance Phase
Zeitfenster: Week 14
|
The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease.
A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
A decrease in CDAI over time indicates improvement in disease activity.
|
Week 14
|
CDAI Score at Week 16 in the Randomized Maintenance Phase
Zeitfenster: Week 16
|
The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease.
A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
A decrease in CDAI over time indicates improvement in disease activity.
|
Week 16
|
CDAI Score at Week 18 in the Randomized Maintenance Phase
Zeitfenster: Week 18
|
The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease.
A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
A decrease in CDAI over time indicates improvement in disease activity.
|
Week 18
|
CDAI Score at Week 20 in the Randomized Maintenance Phase
Zeitfenster: Week 20
|
The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease.
A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
A decrease in CDAI over time indicates improvement in disease activity.
|
Week 20
|
CDAI Score at Week 22 in the Randomized Maintenance Phase
Zeitfenster: Week 22
|
The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease.
A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
A decrease in CDAI over time indicates improvement in disease activity.
|
Week 22
|
CDAI Score at Week 24 in the Randomized Maintenance Phase
Zeitfenster: Week 24
|
The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease.
A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
A decrease in CDAI over time indicates improvement in disease activity.
|
Week 24
|
CDAI Score at Week 26 in the Randomized Maintenance Phase
Zeitfenster: Week 26
|
The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease.
A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
A decrease in CDAI over time indicates improvement in disease activity.
|
Week 26
|
Change From Baseline in CDAI Score at Week 2 of the Induction Phase
Zeitfenster: Baseline to Week 2
|
The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease.
A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
A decrease in CDAI over time indicates improvement in disease activity.
|
Baseline to Week 2
|
Change From Baseline in CDAI Score at Week 4 of the Induction Phase
Zeitfenster: Baseline to Week 4
|
The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease.
A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
A decrease in CDAI over time indicates improvement in disease activity.
|
Baseline to Week 4
|
Change From Baseline in CDAI Score at Week 6 of the Induction Phase
Zeitfenster: Baseline to Week 6
|
The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease.
A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
A decrease in CDAI over time indicates improvement in disease activity.
|
Baseline to Week 6
|
Change From Baseline in CDAI Score at Week 8 in the Randomized Maintenance Phase
Zeitfenster: Baseline to Week 8
|
The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease.
A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
A decrease in CDAI over time indicates improvement in disease activity.
|
Baseline to Week 8
|
Change From Baseline in CDAI Score at Week 10 in the Randomized Maintenance Phase
Zeitfenster: Baseline to Week 10
|
The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease.
A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
A decrease in CDAI over time indicates improvement in disease activity.
|
Baseline to Week 10
|
Change From Baseline in CDAI Score at Week 12 in the Randomized Maintenance Phase
Zeitfenster: Baseline to Week 12
|
The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease.
A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
A decrease in CDAI over time indicates improvement in disease activity.
|
Baseline to Week 12
|
Change From Baseline in CDAI Score at Week 14 in the Randomized Maintenance Phase
Zeitfenster: Baseline to Week 14
|
The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease.
A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
A decrease in CDAI over time indicates improvement in disease activity.
|
Baseline to Week 14
|
Change From Baseline in CDAI Score at Week 16 in the Randomized Maintenance Phase
Zeitfenster: Baseline to Week 16
|
The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease.
A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
A decrease in CDAI over time indicates improvement in disease activity.
|
Baseline to Week 16
|
Change From Baseline in CDAI Score at Week 18 in the Randomized Maintenance Phase
Zeitfenster: Baseline to Week 18
|
The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease.
A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
A decrease in CDAI over time indicates improvement in disease activity.
|
Baseline to Week 18
|
Change From Baseline in CDAI Score at Week 20 in the Randomized Maintenance Phase
Zeitfenster: Baseline to Week 20
|
The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease.
A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
A decrease in CDAI over time indicates improvement in disease activity.
|
Baseline to Week 20
|
Change From Baseline in CDAI Score at Week 22 in the Randomized Maintenance Phase
Zeitfenster: Baseline to Week 22
|
The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease.
A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
A decrease in CDAI over time indicates improvement in disease activity.
|
Baseline to Week 22
|
Change From Baseline in CDAI Score at Week 24 in the Randomized Maintenance Phase
Zeitfenster: Baseline to Week 24
|
The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease.
A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
A decrease in CDAI over time indicates improvement in disease activity.
|
Baseline to Week 24
|
Change From Baseline in CDAI Score at Week 26 in the Randomized Maintenance Phase
Zeitfenster: Baseline to Week 26
|
The CDAI score is used to quantify the symptoms of subjects with Crohn's Disease.
A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
A decrease in CDAI over time indicates improvement in disease activity.
|
Baseline to Week 26
|
Number of Patients Able to Taper and Discontinue Steroids While Maintaining Remission at Week 10 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.
Zeitfenster: Week 10
|
Remission is defined as CDAI score ≤ 150.
|
Week 10
|
Number of Patients Able to Taper and Discontinue Steroids While Maintaining Remission at Week 12 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.
Zeitfenster: Week 12
|
Remission is defined as CDAI score ≤ 150.
|
Week 12
|
Number of Patients Able to Taper and Discontinue Steroids While Maintaining Remission at Week 14 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.
Zeitfenster: Week 14
|
Remission is defined as CDAI score ≤ 150.
|
Week 14
|
Number of Patients Able to Taper and Discontinue Steroids While Maintaining Remission at Week 16 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.
Zeitfenster: Week 16
|
Remission is defined as CDAI score ≤ 150.
|
Week 16
|
Number of Patients Able to Taper and Discontinue Steroids While Maintaining Remission at Week 18 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.
Zeitfenster: Week 18
|
Remission is defined as CDAI score ≤ 150.
|
Week 18
|
Number of Patients Able to Taper and Discontinue Steroids While Maintaining Remission at Week 20 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.
Zeitfenster: Week 20
|
Remission is defined as CDAI score ≤ 150.
|
Week 20
|
Number of Patients Able to Taper and Discontinue Steroids While Maintaining Remission at Week 22 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.
Zeitfenster: Week 22
|
Remission is defined as CDAI score ≤ 150.
|
Week 22
|
Number of Patients Able to Taper and Discontinue Steroids While Maintaining Remission at Week 24 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.
Zeitfenster: Week 24
|
Remission is defined as CDAI score ≤ 150.
|
Week 24
|
Number of Patients Able to Taper and Discontinue Steroids While Maintaining Remission at Week 26 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.
Zeitfenster: Week 26
|
Remission is defined as CDAI score ≤ 150.
|
Week 26
|
Number of Patients Able to Taper and Discontinue Steroids While Maintaining Response at Week 10 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.
Zeitfenster: Week 10
|
Response is defined as at least 100 point decrease in Crohn's Disease Activity Score (CDAI score).
|
Week 10
|
Number of Patients Able to Taper and Discontinue Steroids While Maintaining Response at Week 12 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.
Zeitfenster: Week 12
|
Response is defined as at least 100 point decrease in Crohn's Disease Activity Score (CDAI score).
|
Week 12
|
Number of Patients Able to Taper and Discontinue Steroids While Maintaining Response at Week 14 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.
Zeitfenster: Week 14
|
Response is defined as at least 100 point decrease in Crohn's Disease Activity Score (CDAI score).
|
Week 14
|
Number of Patients Able to Taper and Discontinue Steroids While Maintaining Response at Week 16 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.
Zeitfenster: Week 16
|
Response is defined as at least 100 point decrease in Crohn's Disease Activity Score (CDAI score).
|
Week 16
|
Number of Patients Able to Taper and Discontinue Steroids While Maintaining Response at Week 18 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.
Zeitfenster: Week 18
|
Response is defined as at least 100 point decrease in Crohn's Disease Activity Score (CDAI score).
|
Week 18
|
Number of Patients Able to Taper and Discontinue Steroids While Maintaining Response at Week 20 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.
Zeitfenster: Week 20
|
Response is defined as at least 100 point decrease in Crohn's Disease Activity Score (CDAI score).
|
Week 20
|
Number of Patients Able to Taper and Discontinue Steroids While Maintaining Response at Week 22 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.
Zeitfenster: Week 22
|
Response is defined as at least 100 point decrease in Crohn's Disease Activity Score (CDAI score).
|
Week 22
|
Number of Patients Able to Taper and Discontinue Steroids While Maintaining Response at Week 24 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.
Zeitfenster: Week 24
|
Response is defined as at least 100 point decrease in Crohn's Disease Activity Score (CDAI score).
|
Week 24
|
Number of Patients Able to Taper and Discontinue Steroids While Maintaining Response at Week 26 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline.
Zeitfenster: Week 26
|
Response is defined as at least 100 point decrease in Crohn's Disease Activity Score (CDAI score).
|
Week 26
|
C - Reactive Protein (CRP) Level at Baseline (Week 0) of the Induction Phase
Zeitfenster: Week 0
|
High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.
|
Week 0
|
CRP Level at Week 2 of the Induction Phase
Zeitfenster: Week 2
|
High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.
|
Week 2
|
CRP Level at Week 4 of the Induction Phase
Zeitfenster: Week 4
|
High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.
|
Week 4
|
CRP Level at Week 6 of the Induction Phase
Zeitfenster: Week 6
|
High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.
|
Week 6
|
CRP Level at Week 8 in the Randomized Maintenance Phase
Zeitfenster: Week 8
|
High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.
|
Week 8
|
CRP Level at Week 10 in the Randomized Maintenance Phase
Zeitfenster: Week 10 (optional measurement)
|
High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.
|
Week 10 (optional measurement)
|
CRP Level at Week 12 in the Randomized Maintenance Phase
Zeitfenster: Week 12
|
High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.
|
Week 12
|
CRP Level at Week 14 in the Randomized Maintenance Phase
Zeitfenster: Week 14 (optional measurement)
|
High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.
|
Week 14 (optional measurement)
|
CRP Level at Week 16 in the Randomized Maintenance Phase
Zeitfenster: Week 16
|
High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.
|
Week 16
|
CRP Level at Week 18 in the Randomized Maintenance Phase
Zeitfenster: Week 18 (optional measurement)
|
High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.
|
Week 18 (optional measurement)
|
CRP Level at Week 20 in the Randomized Maintenance Phase
Zeitfenster: Week 20
|
High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.
|
Week 20
|
CRP Level at Week 22 in the Randomized Maintenance Phase
Zeitfenster: Week 22 (optional measurement)
|
High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.
|
Week 22 (optional measurement)
|
CRP Level at Week 24 in the Randomized Maintenance Phase
Zeitfenster: Week 24
|
High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.
|
Week 24
|
CRP Level at Week 26 in the Randomized Maintenance Phase
Zeitfenster: Week 26
|
High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.
|
Week 26
|
CRP Level at Endpoint (Last Visit) in the Randomized Maintenance Phase
Zeitfenster: Last visit on or before Week 26
|
High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.
Endpoint is the visit when the last observation was taken, either at week 26 or at a visit before in case of early dropout.
|
Last visit on or before Week 26
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Time to Loss of Response (CDAI Score > 150 and Minimum Increase in CDAI of 70) After Week 6
Zeitfenster: Week 6 to Week 26
|
Median time to loss of response in the maintenance period (from Kaplan-Meier analysis); range is time of first event to time of last event.
Loss of response is defined as both a CDAI score > 150 points and a minimum increase in CDAI of 70 points versus Week 6 at two consecutive visits.
|
Week 6 to Week 26
|
Mitarbeiter und Ermittler
Sponsor
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Taylor P, Manger B, Alvaro-Gracia J, Johnstone R, Gomez-Reino J, Eberhardt E, Wolfe F, Schwartzman S, Furfaro N, Kavanaugh A. Patient perceptions concerning pain management in the treatment of rheumatoid arthritis. J Int Med Res. 2010 Jul-Aug;38(4):1213-24. doi: 10.1177/147323001003800402.
- Sandborn WJ, Abreu MT, D'Haens G, Colombel JF, Vermeire S, Mitchev K, Jamoul C, Fedorak RN, Spehlmann ME, Wolf DC, Lee S, Rutgeerts P. Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab. Clin Gastroenterol Hepatol. 2010 Aug;8(8):688-695.e2. doi: 10.1016/j.cgh.2010.04.021. Epub 2010 May 6.
- Feagan BG, Sandborn WJ, Wolf DC, Coteur G, Purcaru O, Brabant Y, Rutgeerts PJ. Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn's disease with prior loss of response to infliximab. Aliment Pharmacol Ther. 2011 Mar;33(5):541-50. doi: 10.1111/j.1365-2036.2010.04568.x. Epub 2011 Jan 12.
Nützliche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- C87042
- Eudract number: 2005-004104-37
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Certolizumab pegol
-
Atlanta Gastroenterology AssociatesUCB PharmaUnbekannt
-
Nathan Wei, MD, FACP, FACR:University of California, San DiegoAbgeschlossenRheumatoide ArthritisVereinigte Staaten
-
UCB Pharma SAAbgeschlossenMorbus CrohnVereinigte Staaten, Australien, Österreich, Weißrussland, Belgien, Bulgarien, Kanada, Tschechien, Dänemark, Estland, Deutschland, Ungarn, Israel, Italien, Neuseeland, Norwegen, Polen, Russische Föderation, Serbien, Singapur, Slo... und mehr
-
University of WashingtonUniversity of Pennsylvania; UCB PharmaAbgeschlossenColitis ulcerosaVereinigte Staaten
-
UCB PharmaAbgeschlossenRheumatoide ArthritisDänemark, Niederlande, Polen, Schweden
-
UCB PharmaAbgeschlossenMorbus CrohnVereinigte Staaten, Frankreich, Italien, Vereinigtes Königreich, Belgien, Deutschland, Spanien, Schweiz, Kanada, Niederlande, Österreich, Schweden
-
UCB PharmaAbgeschlossenRheumatoide ArthritisVereinigte Staaten, Frankreich, Italien, Deutschland, Spanien, Kanada, Niederlande
-
UCB Biopharma SRLAbgeschlossenPlaque-PsoriasisBelgien, Kanada, Tschechien, Frankreich, Deutschland, Griechenland, Italien, Spanien, Vereinigtes Königreich